Why is CRVS down?
Down 31% in 3 months while the S&P 500 fell 10%.
- Its share count rose 11.7% in a year,
−1Long-term trend
Down 31% in 3 months while the S&P 500 fell 10%.
−1Long-term trend
CRVS's Quality Score rose 1 point on Fri, Nov 20, to -2. It had its calmest day in a week.
Follow CRVS's trial news. Pro members can get an alert when Corvus Pharmaceuticals files news, and see its trials, share raises, and its CEO's filings.
We do the work for you. Every stock is scored and ranked, every 15 seconds while the market is open. Here it's 15 minutes behind. Pro members see it live.
| Holding it back | A $64M loss |
| Latest filing | 8-K, Nov 5 |
Sat Dec 12: American Society of Hematology…Industry event · date confirmed.
After its last 4 reports it closed +2.8% on average, higher 3 of 4 times.
The company says its cash lasts into second quarter 2028 (8-K, Nov 5).
Chief Business Officer Jeffrey Arcara bought 4,500 shares on Nov 13. 2 more insider trades this year.
Decision dates and advisory committee meetings the companies have announced in their filings, soonest first and small companies first.
CRVS is #143 of 273 by Quality Score.
| Rank | Stock | Quality Score |
|---|---|---|
| 1 | ||
| 2 | ||
| 3 | ||
| Open for its score | ||
| Open for its score | ||
| Open for its score | ||
| Open for its score | ||
| 143 |
Expected to report Thu Mar 11, after the close (in 110 days).
What an earnings report is: every 3 months, a company tells everyone how much it sold and earned. We read the figures, the outlook, and how the stock moved after.
A loss of $0.22 a share, from $0.12.
“The increase in research and development expenses of $9.3 million was primarily due to higher clinical trial costs associated with the development of soquelitinib as well as an increase in personnel related costs.”
CRVS's results filing gives no sales by line in a table we read.
No outlook figures read from this release.
“Based on its current plans, Corvus expects its cash, cash equivalents and marketable securities to fund operations into the second quarter of 2028.”
From its results filing (SEC filing · Nov 5)
| Reported | Gap | Reaction | 5 days |
|---|---|---|---|
| Nov 5, 2026 | +9.5% | +8.3% | +9.2% |
| Aug 6, 2026 | -6.9% | +0.4% | +9.2% |
| May 7, 2026 | +1.5% | +6.6% | -6.4% |
RSI 39.6, MACD below signal, below both averages. Not scored.
2 insiders bought $301K across 5 filings in the last 6 months. No open-market sales on record. The newest:
Officers and directors with a Form 4 in the last 12 months.
In ETFs: CRVS is under 0.1% of VTI, the most of the 24 funds Breakaway covers, by their holdings as filed for Jun 30, 2026.
Corvus Pharmaceuticals Inc is a clinical stage biopharmaceutical company developing product candidates that precisely target proteins that are critical to immune cell maturation and function. It believes its proprietary product candidates have broad potential to address immune mediated diseases, inflammatory diseases and cancers. Its product candidate, soquelitinib, is designed to bind specifically to a protein, interleukin 2 inducible T cell kinase (ITK), involved in T cell activation, T cell receptor signaling and T cell differentiation and function. The company operates in one primary business activity and operate as one reportable segment.
CRVS scores -2 today, which Breakaway calls Poor. It is #143 of 273 in Biotech by Quality Score, with 1 of 14 chart checks firing. Down 31% in 3 months while the S&P 500 fell 10%. Shares: 11.7% more than a year ago (to Sep 30). Breakaway does not say whether to buy any stock: the score does not know your situation, and it is not a recommendation to buy or sell anything. Please do your own research.
CRVS scores -2 today, which Breakaway calls Poor (below zero). That is #143 of 273 in Biotech by Quality Score. The score adds up the chart checks, the trend, the company's filed sales, its profits, the news, insider trades, and Congress trades. The section above lists the lines behind CRVS's -2.
2 insiders bought $301K across 5 filings in the last 6 months. No open-market sales on record. The newest is Jeffrey Arcara, Chief Business Officer, who bought $34K on Nov 11. Every filing, with the scored weight, for Pro members.
Only on the public pages, which run at least 15 minutes behind. Pro members, and anyone on a guest pass, see real-time prices: the scanner refreshes every 15 seconds, and your watchlist every few seconds, pre-market and after hours included.
Only on the public pages, which run at least 15 minutes behind. Pro members see real-time prices: the scanner refreshes every 15 seconds, and your watchlist every few seconds, pre-market and after hours included. The one stock you open in full is live too.
Insider and Congress trades, the chart, and the financials, in one score.
See it live, free until Tuesday morning. No account. No card.One stock in full, free. No account.$1 for a first month of Pro. Then $39 a month. Then keep going with a free account.Then $1 for a first month of Pro.Then 7 days of Pro free, with a card.